gip/glp-1 agonists GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica GLP-1 Receptor Agonists Explained for

The analysis showed significantly greater WL in the GLP-1RAs group compared to placebo (SMD=0.82, 95% CI 0.23 to 1.42)

This article thoroughly traces the developmental milestones of GLP-1 drugs, from their initial discovery to their clinical application, detailing the evolution of diverse GLP-1 medications along with their distinct pharmacological properties

This article looks at the unwanted side effects of glucagon-like peptide-1 (GLP-1) receptor agonists

Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality

While they can be highly effective for many patients, they are